Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | LPL | P06858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16612434 | 0.94 | KDM4E (0.47) | KDM4EALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL16491292 | 0.85 | PDK2 (0.50) | KDM4EALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL16468543 | 0.85 | CA1 (0.48) | KDM4EALDH1A1SMN1; SMN2ADRA1AADRA1B | |
| SCHEMBL1129541 | 0.85 | CHRNB2 (0.52) | KDM4EALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL18124821 | 0.82 | LIPG (0.50) | LIPGLPL | |
| SCHEMBL27075535 | 0.81 | LIPG (0.43) | KDM4EALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL20600192 | 0.80 | SLC6A9 (0.43) | — | |
| SCHEMBL16491289 | 0.80 | PDK2 (0.45) | KDM4EALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL1561010 | 0.80 | KDM4E (0.52) | KDM4EMAPTKMT2ASMN1; SMN2LIPG | |
| SCHEMBL1572881 | 0.80 | LMNA (0.54) | KDM4EALDH1A1LMNALIPGLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751887-B2 | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| EP-2857404-B1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO CO LTD (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-20160046639-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-02-18 | — | — | US | disclosed |
| EP-2857404-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046639-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | ROS1, JAK1, ERBB2 | KDM4E 2596/4885ALDH1A1 860/4885LMNA 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.